Russian Drugs Show Promise in Treating Adolescent Obesity
- Published:
- First detected:
Insights by Echo AI
Russian pharmaceutical company 'Geropharm' has presented promising results from clinical trials of its drugs 'Semaglumet', 'Semaglutide Next', 'Sedjaro', and 'Semavik Next' for treating adolescent obesity. The trials involved around 800 children aged 12-17 with II-III degree obesity. After six months of therapy, participants showed an average weight loss of approximately 20%, transitioning from severe obesity to a healthy weight range. There was also a decrease in associated chronic diseases and an improvement in lifestyle. The drugs are expected to be available for treating this condition in teenagers by 2027.
Source coverage
7
records merged
0
0 unique
7
7 unique
0
0 unique
7 Sources
Unlock Echo Intelligence
Move beyond the public feed. Monitor breaking stories across Telegram, X, and the web — with earlier visibility, clearer context, and complete control over your sources.
- Monitor Telegram, X, and web in one place
- Add any source, from niche channels to global outlets
- Build custom feeds around events, regions, entities, or keywords
- Merge duplicate coverage into one clear, source-transparent story
- Auto-translate summaries and full articles
- Search past coverage and use AI-powered editorial tools
